Effects of ICI 182,780, an ERα and ERβ antagonist, and G-1, a GPER agonist, on autophagy in breast cancer cells by Mari Luminosa Muler, Fernanda Antunes, Gabriel Cicolin Guarache, Rafaela Brito Oliveira, Rodrigo Portes Ureshino, Claudia Bincoletto, Gustavo José da Silva Pereira, Soraya Soubhi Smaili

“…ABSTRACT Objective To investigate if ICI 182,780 (fulvestrant), a selective estrogen receptor alpha/beta (ERα/ERβ) antagonist, and G-1, a selective G-protein-coupled receptor (GPER) agonist, can potentially induce autophagy in breast cancer cell lines MCF-7 and SKBr3, and how G-1 affects cell viability. …”
Get full text

An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment by Xiaowei Wang, Wenjia Su, Dabei Tang, Jing Jing, Jing Xiong, Yuwei Deng, Huili Liu, Wenjie Ma, Zhaoliang Liu, Qingyuan Zhang

“…With the significantly improved survival rate of TNBC patients treated with ICI therapies, a biomarker integrating multiple aspects of TIME may have prognostic value for improving the efficacy of ICI therapy. …”
Get full text

Subzero saline chilling with or without prechilling in icy water improved chilling efficiency and meat tenderness of broiler carcasses by K. Kawamura, D. Ma, A. Pereira, D.U. Ahn, D.M. Kim, I. Kang

“…Color (L*, a*, and b*) values were evaluated on both breast skin and skinless breast surfaces. Meat tenderness was evaluated using the breast fillets after overnight storage and cooking to an internal temperature of 76°C. …”
Get full text

A real‐world study of immune checkpoint inhibitors in advanced triple‐negative breast cancer by Zheng Zhang, Yadi Zhang, Chuanling Liu, Jiakang Shao, Yimeng Chen, Yimin Zhu, Li Zhang, Boyu Qin, Ziqing Kong, Xixi Wang, Yutong Wang, Deqin Huang, Liqun Liu, Yuxin Zhou, Ran Tao, Zengjie Yang, Mei Liu, Weihong Zhao

“…Abstract Background Triple‐negative breast cancer (TNBC) is the most aggressive type of breast cancer. …”
Get full text

Serotonin after β-Adrenoreceptors’ Exposition: New Approaches for Personalized Data in Breast Cancer Cells by Ana Salomé Correia, Diana Duarte, Isabel Silva, Henrique Reguengo, José Carlos Oliveira, Nuno Vale

“…Previously, our group reported that β-adrenergic drugs (ICI 118,551, isoprenaline, and propranolol) influence the proliferation of breast cancer cells (MCF-7 cells) and their inherent production of adrenaline. …”
Get full text

Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer by Flavia Jacobs, Elisa Agostinetto, Chiara Miggiano, Rita De Sanctis, Alberto Zambelli, Armando Santoro

Subjects: “…triple-negative breast cancer…”
Get full text

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer by Kassidy M. Jungles, Kassidy M. Jungles, Kassidy M. Jungles, Erin A. Holcomb, Ashley N. Pearson, Kalli R. Jungles, Caroline R. Bishop, Lori J. Pierce, Lori J. Pierce, Michael D. Green, Michael D. Green, Michael D. Green, Michael D. Green, Corey W. Speers, Corey W. Speers, Corey W. Speers

Subjects: “…immune checkpoint inhibitors (ICI)…”
Get full text

Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer by Daniel Cook, Matthew Biancalana, Nicole Liadis, Dorys Lopez Ramos, Yuhan Zhang, Snehal Patel, Joseph R. Peterson, John R. Pfeiffer, John A. Cole, Anuja K. Antony

“…BackgroundImmuno-oncology (IO) therapies targeting the PD-1/PD-L1 axis, such as immune checkpoint inhibitor (ICI) antibodies, have emerged as promising treatments for early-stage breast cancer (ESBC). …”
Get full text

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer by Ashley Schreier, Roberta Zappasodi, Roberta Zappasodi, Roberta Zappasodi, Inna Serganova, Inna Serganova, Kristy A. Brown, Sandra Demaria, Eleni Andreopoulou

Subjects: “…triple negative breast cancer (TNBC)…”
Get full text

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis by Muhammad Khan, Muhammad Khan, Kunpeng Du, Kunpeng Du, Meiling Ai, Meiling Ai, Baiyao Wang, Baiyao Wang, Jie Lin, Jie Lin, Anbang Ren, Anbang Ren, Chengcong Chen, Chengcong Chen, Zhong Huang, Zhong Huang, Wenze Qiu, Wenze Qiu, Yawei Yuan, Yawei Yuan, Yunhong Tian, Yunhong Tian

Subjects: “…breast cancer…”
Get full text

Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review by Yuxin Ma, Xinhong Shi, Kun Zhao, Shuyi Hu, Yue Shi, Yingying Jiang, Yiling Liu, Lin Lu, Yuting Chang, Fei Zhou, Yingying Dai, Zipeng Wu, Shiyi Li, Zhiying Qian, Xia Xu, Chenchen Li, Bo Shen, Bo Shen, Guoren Zhou, Cheng Chen, Xiaohua Wang, Xiaohua Wang, Jifeng Feng, Jifeng Feng

Subjects: “…metastatic triple negative breast cancer (mTNBC)…”
Get full text

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid by Aggeliki K. Meligova, Dimitra Siakouli, Sotiria Stasinopoulou, Despoina S. Xenopoulou, Maria Zoumpouli, Vassiliki Ganou, Eleni-Fani Gkotsi, Aristotelis Chatziioannou, Olga Papadodima, Eleftherios Pilalis, Michael N. Alexis, Dimitra J. Mitsiou

Subjects: “…breast cancer…”
Get full text

Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC) by Yulan Gong, Rajeswari Nagarathinam, Maria F. Arisi, Lorenzo Gerratana, Jennifer S. Winn, Michael Slifker, Jianming Pei, Kathy Q. Cai, Zachary Hasse, Elias Obeid, Julio Noriega, Christopher Sebastiano, Eric Ross, Katherine Alpaugh, Massimo Cristofanilli, Sandra V. Fernandez

Get full text

Imunoterapia no cancro de mama triplo-negativo: o papel dos inibidores de checkpoint imunológico by Susana Branco, Maria Inês Graça, Sara Morais

Subjects: “…Triple-negative breast cancer…”
Get full text

Advances in immunotherapy for triple-negative breast cancer by Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu, Xi Gu

“…This review highlights the unique tumor microenvironment of TNBC and integrates and analyzes the advances in ICI therapy. It also discusses strategies for the combination of ICIs with chemotherapy, radiation therapy, targeted therapy, and emerging treatment methods such as nanotechnology, ribonucleic acid vaccines, and gene therapy. …”
Get full text

Immunotherapy Treatment for Triple Negative Breast Cancer by Elizabeth R. Berger, Tristen Park, Angeleke Saridakis, Mehra Golshan, Rachel A. Greenup, Nita Ahuja

“…Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. …”
Get full text

Opportunities for Antigen Discovery in Metastatic Breast Cancer by Ashwani K. Sood, Michael Nemeth, Michael Nemeth, Jianmin Wang, Yun Wu, Shipra Gandhi

“…Immune checkpoint inhibitor-based immunotherapy (ICI) of breast cancer is currently efficacious in a fraction of triple negative breast cancers (TNBC) as these cancers generally carry high tumor mutation burden (TMB) and show increased tumor infiltration by CD8+ T cells. …”
Get full text

Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer by Chi Yan, Jinming Yang, Nabil Saleh, Sheau-Chiann Chen, Gregory D. Ayers, Vandana G. Abramson, Ingrid A. Mayer, Ann Richmond

“…Objectives: Inhibition of the PI3K/mTOR pathway suppresses breast cancer (BC) growth, enhances anti-tumor immune responses, and works synergistically with immune checkpoint inhibitors (ICI). …”
Get full text

Automated diagnosis of breast cancer using deep learning by Iustin FLOROIU, Daniela TIMISICĂ, Radu Marius BONCEA

Get full text

Immunological barriers to immunotherapy in primary and metastatic breast cancer by Mara De Martino, Claire Vanpouille‐Box, Lorenzo Galluzzi

“…Patients with breast cancer obtain limited clinical benefits from immune checkpoint inhibitors (ICIs), pointing to the existence of multiple immunological alterations that cannot be simultaneously normalized with immunotherapy. …”
Get full text